

UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS V LLC;
HAYMAN CREDES MASTER FUND, L.P.;
HAYMAN ORANGE FUND SPC – PORTFOLIO A;
HAYMAN CAPITAL MASTER FUND, L.P.;
HAYMAN CAPITAL MANAGEMENT, L.P.;
HAYMAN OFFSHORE INVESTMENTS, LLC;
NXN PARTNERS, LLC;
IP NAVIGATION GROUP, LLC;
KYLE BASS, and ERICH SPANGENBERG,
Petitioners,

v.

BIOGEN MA INC.,
Patent Owner,

Case IPR2015-01993
Patent 8,399,514 B2

BIOGEN MA INC.,
Junior Party,
Patent 8,399,514 B2,

v.

FORWARD PHARMA A/S
Senior Party,
Application 11/576,871.

Order
Oral Arguments

Before RICHARD E. SCHAFER, Administrative Patent Judge.

Oral arguments in the above proceedings are set to begin at 9:30 a.m., November 30, 2016, in Hearing Room B, 9th Floor, Madison Building East, 600 Dulany Street, Alexandria, Virginia,¹

The arguments in IPR 2014-01993 will be heard first. Each party will have 20 minutes. Petitioner will present its argument first. Each party may save a portion of its time for rebuttal. The Board will then take a short recess to allow the interference parties to set up for their arguments in Interference 106,023. Each party in interference 106,023 will have 30 minutes and may save a portion of that time for rebuttal. The junior party will present its arguments first.

The hearing will be open to the public. In-person attendance will be accommodated on a first-come, first-served basis.

The Board will provide a court reporter for the hearing and the reporter's transcript will constitute the official record of the hearing. Any demonstrative exhibits must be served seven business days before the hearing. The demonstratives shall not be filed with the Board. A hard copy of the demonstratives shall be provided to each APJ and to the court reported at the beginning of the argument. Neither the oral argument nor demonstrative exhibits constitute evidence (other than possible admissions). The demonstratives may not

¹ Oral argument in IPR2015-01993 is tentative pending the submission of a request for oral argument by Coalition and Biogen as set in the Scheduling Order of April 19, 2016 (Paper 34).

introduce new evidence or argument. Demonstrative exhibits must cite to the location of the evidence in the record.

Questions regarding specific audio-visual equipment should be directed to the Board at (571) 272-9797. Requests for audio-visual equipment are to be made five (5) days in advance of the hearing date. The request is to be sent to Trials@uspto.gov. If the request is not timely received, the equipment may not be available on the day of the hearing. The parties are reminded that the presenter must identify clearly and specifically each demonstrative exhibit (e.g., by slide or screen number) referenced during the hearing to ensure the clarity and accuracy of the reporter's transcript.

Counsel for Coalition for Affordable Drugs:

James T. Carmichael
Carol A. Spiegel
Carmichael IP, PLLC
jim@carmichaelip.com
carol@carmichaelip.com

Counsel for Biogen MA Inc.:

Michael Flibbert
Maureen D. Queler
Erin M. Sommers
Michele C. Bosch
Barbara C. McCurdy
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Michael.flibbert@finnegan.com
Maureen.queler@finnegan.com
Erin.sommers@finnegan.com
Michele.bosch@finnegan.com
Barbara.mccurdy@finnegan.com

Counsel for Forward Pharma A/S:

Anthony M. Zupcic
Daniel S. Glueck
Fitzpatrick, Cella, Harper & Scinto
Azupcic@fchs.com
Dglueck@fchs.com

Brian V. Slater
Kramer Levin Naftalis & Frankel, LLP
BSlater@kramerlevin.com